Yet again, a jury sent AbbVie, maker of the popular prescription testosterone drug Androgel, a loud and clear message. A federal jury in Chicago found that AbbVie misrepresented the dangers of using Androgel. And to make sure the drugmaker got their message, it also reached a verdict in excess of $140 million.
This most recent trial is the second bellwether case to be tried in the federal testosterone replacement ...
continue reading...One would think that a verdict of this magnitude would send a very loud, very clear message to Androgel maker AbbVie. Unfortunately, the testosterone therapy maker may actually escape paying on this verdict, calling into question whether the company will still “hear” the jury.
The $150 million testosterone verdict was just issued in the case of an Oregon man whose lawsuit accused AbbVie of hiding ...
continue reading...
AbbVie, maker of the popular testosterone therapy product AndroGel, has expressed dissatisfaction with the federal court’s bellwether trial selection process, Forbes reports. The U.S. District Court for the Northern District of Illinois has chosen AbbVie to defend in the first MDL testosterone lawsuit to go to trial. AbbVie, a defendant in the fast-growing Illinois testosterone therapy MDL, has been instructed to select 32 potential cases to be prepared for ...
The most recent report from the U.S. Judicial Panel on Multidistrict Litigation shows 2,231 testosterone lawsuits included in the Illinois MDL —and there’s no sign that the flood of lawsuits will let up any time soon. According to the Public Access to Court Electronic Records (PACER) database, over 40 new testosterone lawsuits were filed in the last week alone. A testosterone lawsuit filed last month by a ...
We recently posted an update detailing the 4.3% rise in AbbVie’s first-quarter profits. One year ago, the pharmaceutical giant posted profits of $980 million for the first three months of 2014. That, apparently, wasn’t enough. The first three months of 2015 saw profits of $1.02 billion for the Androgel manufacturer.
Profit is not a bad thing. Profit is how bills are paid, families are fed, and companies are ...
continue reading...Pharmaceutical giant AbbVie, Inc. has reported a 4.3 percent increase in its first-quarter profits, according to Nasdaq. The Chicago-based company cited heightened sales of anti-inflammatory medications, and detailed its plans to keep its top-selling drug Humira afloat.
Despite the rise in profits, AbbVie still faces financial trouble in the form of testosterone lawsuits. The company’s popular “low-T” product, AndroGel, is one of a handful or prescription testosterone ...
continue reading...
